Findings

What do systematic reviews say?

137 questions · 137 findings · 8 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 46 · 33.6%GRADE not reported 3 · 2.2%Very low 21 · 15.3%Low 40 · 29.2%Moderate 21 · 15.3%High 6 · 4.4%

Web‐based application to record, monitor and set goals on physical activity plus usual care vs usual care

Exercise capacity · adolescents and adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Web‐based vs face‐to‐face exercise delivery

Adherence to exercise training (long term) · children and adults with CF

The review found no eligible studies for this question.

1 finding from 1 review

Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Web‐based vs face‐to‐face exercise delivery

Self‐management behavior (long term) · children and adults with CF

The review found no eligible studies for this question.

1 finding from 1 review

Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Web‐based vs face‐to‐face exercise delivery

QoL · children and adults with CF

The review found no eligible studies for this question.

1 finding from 1 review

Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Exercise prescription plus the use of a wearable fitness tracker vs exercise

QoL · adults with CF

The review found no eligible studies for this question.

1 finding from 1 review

Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Exercise prescription plus the use of a wearable fitness tracker vs exercise

Exercise capacity · adults with CF

The review found no eligible studies for this question.

1 finding from 1 review

Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Wearable fitness tracker plus text message for personalized feedback and goal setting vs wearable fitness tracker alone

Adherence to exercise training (long term) · adults with CF

The review found no eligible studies for this question.

1 finding from 1 review

Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Wearable fitness tracker plus text message for personalized feedback and goal setting vs wearable fitness tracker alone

Self‐management behavior (long term) · adults with CF

The review found no eligible studies for this question.

1 finding from 1 review

Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Recombinant human growth hormone vs placebo or no intervention

Change in height · children with X‐linked hypophosphataemia

Summary of findings ‐ recombinant growth hormone showed no clear difference in longitudinal growth: change in height SDS compared with placebo or no intervention (low certainty).

1 finding from 1 review

Recombinant growth hormone therapy for X‐linked hypophosphatemia in children 2021 · Cochrane Headline outcomes only
MD 0
2 studies · 20 participants
Low

Pine bark extract vs placebo

California verbal learning test: long‐delay free recall scores · adults with a traumatic brain injury

1 finding from 1 review

Pine bark (Pinus spp.) extract for treating chronic disorders 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 56 participants
Very low

Summary of findings: anti‐pseudomonal antibiotics vs placebo

FEV1 % predicted · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 1130 participants
Low

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

Pulmonary exacerbations · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: colistimethate dry powder for inhalation… showed no clear difference in pulmonary exacerbations: number of pulmonary exacerbations compared with tobramycin (moderate certainty).

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
RR 1.19 [0.86, 1.64]
1 study · 374 participants
Moderate

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

QoL · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 374 participants
Low

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

Survival: number of deaths · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: colistimethate dry powder for inhalation… showed no clear difference in survival: number of deaths compared with tobramycin (low certainty).

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
RR 0.21 [0.01, 4.32]
1 study · 374 participants
Low

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

Antibiotic resistance: change in mean MIC50 and MIC90 at the end of the trial · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 374 participants
Low

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

Adverse events: number of treatment related adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: colistimethate dry powder for inhalation… may leads to higher adverse events: number of treatment related adverse events compared with tobramycin (low certainty).

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
RR 1.76 [1.5, 2.08]
1 study · 379 participants
Low

Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 32 participants
Very low

Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 32 participants
Very low

Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin

Pulmonary exacerbations · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin

Quality of life · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found